S. Shailaja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
S. Shailaja has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Susweta Das Mitra
Department of Biotechnology, School of Basic & Applied Sciences (SBAS), Dayananda Sagar university, Bangalore, Karnataka, India
3 shared publications Jyotibrata Mitra
2 shared publicationsAdrija Saha
1 shared publicationAmeera
1 shared publication- Aneesa Fasim
School of Basic and Applied Sciences, Dayananda Sagar University, Bengaluru, India
1 shared publication Harshitha N
1 shared publication
Latest Publications
- Open Access
- 21 January 2025
- Published by Elsevier in Industrial Crops and Products
- Vol. 225
Hydrogel integrating CBEO-CINcocktail (Cinnamomum pauciflorum Nees bark oil enriched with cinnamaldehyde) loaded nanosponges exhibited potent antibacterial activity against carbapenem resistant bacterial pathogens - in vitro and in vivo evaluation
- 21 January 2025
- Published by Elsevier in Industrial Crops and Products
- Vol. 225
Open AccessHydrogel integrating CBEO-CINcocktail (Cinnamomum pauciflorum Nees bark oil enriched with cinnamaldehyde) loaded nanosponges exhibited potent antibacterial activity against carbapenem resistant bacterial pathogens - in vitro and in vivo evaluation
- 20 April 2023
- Published by Elsevier in Industrial Crops and Products
- Vol. 198
Essential oil and phytoconstituent (Linalool) from Homalomena aromatica Schott. rhizomes exhibit antibacterial and synergistic effects with beta-lactam antibiotics against Carbapenem-resistant Enterobacteriaceae (CRE) and Methicillin Resistant S. aureus (MRSA) pathogens
- 20 April 2023
- Published by Elsevier in Industrial Crops and Products
- Vol. 198
Essential oil and phytoconstituent (Linalool) from Homalomena aromatica Schott. rhizomes exhibit antibacterial and synergistic effects with beta-lactam antibiotics against Carbapenem-resistant Enterobacteriaceae (CRE) and Methicillin Resistant S. aureus (MRSA) pathogens
- 27 September 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (16) , 7700-7711
Identification of a potential inhibitor for New Delhi metallo-β-lactamase 1 (NDM-1) from FDA approved chemical library- a drug repurposing approach to combat carbapenem resistance
Superbugs producing New Delhi metallo-β-lactamase 1 (NDM-1) enzyme is a growing crisis, that is adversely affecting the global health care system. NDM-1 empowers the bacteria to inactivate entire arsenal of β-lactam antibiotics including carbapenem (the last resort antibiotic) and remains ineffective to all the available β lactamase inhibitors used in the clinics. Limited therapeutic option available for rapidly disseminating NDM-1 producing bacteria makes it imperative to identify a potential inhibitor for NDM-1 enzyme. With drug repurposing approach, in this study, we used virtual screening of available Food and Drug Administration (FDA) approved chemical library (ZINC12 database) and captured ‘adapalene’ (FDA drug) as a potent inhibitor candidate for NDM-1 enzyme. Active site docking with NDM-1, showed adapalene with binding energy −9.21 kcal/mol and interacting with key amino acid residues (Asp124, His122, His189, His250, Cys208) in the active site of NDM-1. Further, molecular dynamic simulation of NDM-1 docked with the adapalene at 100 ns displayed a stable conformation dynamic, with relative RMSD and RMSF in the acceptable range. Subsequently, in vitro enzyme assays using recombinant NDM-1 protein demonstrated inhibition of NDM-1 by adapalene. Further, the combination of adapalene plus meropenem (carbapenem antibiotic) showed synergistic effect against the NDM-1 producing carbapenem (meropenem) resistant clinical isolates (Escherichia coli and Klebsiella pneumoniae). Overall, our data indicated that adapalene can be a potential inhibitor candidate for NDM-1 enzyme that can contribute to the development of a suitable adjuvant to save the activity of carbapenem antibiotic against infections caused by NDM-1 positive gram-negative bacteria. Communicated by Ramaswamy H. Sarma
- 27 September 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (16) , 7700-7711
Identification of a potential inhibitor for New Delhi metallo-β-lactamase 1 (NDM-1) from FDA approved chemical library- a drug repurposing approach to combat carbapenem resistance
Superbugs producing New Delhi metallo-β-lactamase 1 (NDM-1) enzyme is a growing crisis, that is adversely affecting the global health care system. NDM-1 empowers the bacteria to inactivate entire arsenal of β-lactam antibiotics including carbapenem (the last resort antibiotic) and remains ineffective to all the available β lactamase inhibitors used in the clinics. Limited therapeutic option available for rapidly disseminating NDM-1 producing bacteria makes it imperative to identify a potential inhibitor for NDM-1 enzyme. With drug repurposing approach, in this study, we used virtual screening of available Food and Drug Administration (FDA) approved chemical library (ZINC12 database) and captured ‘adapalene’ (FDA drug) as a potent inhibitor candidate for NDM-1 enzyme. Active site docking with NDM-1, showed adapalene with binding energy −9.21 kcal/mol and interacting with key amino acid residues (Asp124, His122, His189, His250, Cys208) in the active site of NDM-1. Further, molecular dynamic simulation of NDM-1 docked with the adapalene at 100 ns displayed a stable conformation dynamic, with relative RMSD and RMSF in the acceptable range. Subsequently, in vitro enzyme assays using recombinant NDM-1 protein demonstrated inhibition of NDM-1 by adapalene. Further, the combination of adapalene plus meropenem (carbapenem antibiotic) showed synergistic effect against the NDM-1 producing carbapenem (meropenem) resistant clinical isolates (Escherichia coli and Klebsiella pneumoniae). Overall, our data indicated that adapalene can be a potential inhibitor candidate for NDM-1 enzyme that can contribute to the development of a suitable adjuvant to save the activity of carbapenem antibiotic against infections caused by NDM-1 positive gram-negative bacteria. Communicated by Ramaswamy H. Sarma